Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Shepherd FA , Dancey J , Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy. J. Clin. Oncol. 18, 2095–2103 (2000).
  Medline CASGoogle Scholar
• 2. Keir ME , Butte MJ , Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
  Medline CASGoogle Scholar
• 3. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  Medline CASGoogle Scholar
• 4. Brahmer J , Reckamp K , Baas P et al. Nivolumab versus docetaxel in advanced squamous cell non small cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015). •• Key study demonstrating a greater efficacy with the anti-PD-1 nivolumab compared with standard chemotherapy in pretreated squamous non-small-cell lung cancer (NSCLC) patients.
  Medline CASGoogle Scholar
• 5. Borghaei H , Paz-Ares L , Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non small cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015). •• Key study demonstrating a greater efficacy with the anti-PD-1 nivolumab compared with standard chemotherapy in pretreated nonsquamous NSCLC patients.
  Medline CASGoogle Scholar
• 6. Herbst RS , Baas P , Kim DV et al. Pembrolizumab versus docetaxel for previously treated PD-L1 positive advanced non small cell lung cancer (KEINOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016). •• Key study demonstrating a greater efficacy with the anti-PD-1 pembrolizumab compared with standard chemotherapy in pretreated NSCLC patients.
  Medline CASGoogle Scholar
• 7. Rittmeyer A , Barlesi F , Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non small cell lung cancer (OAK): a Phase 3, open-label, multicenter randomized controlled trial. Lancet 389, 255–265 (2017). •• Key study demonstrating a greater efficacy with the anti-PD-L1 atezolizumab compared with standard chemotherapy in pretreated NSCLC patients.
  MedlineGoogle Scholar
• 8. Horn L , Spigel DR , Vokes EE et al. Nivolumab versus docetaxel in previously treated patients with advanced non small cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924–3933 (2017).
  Medline CASGoogle Scholar
• 9. Herbst RS , Garon EB , Kim D et al. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro). Ann. Oncol. 29 (Suppl. 8), LBA63 (2018).
  Google Scholar
• 10. Fehrenbacher L , von Pawel J , Park K et al. Updated efficacy analysis including secondary population results for OAK: a randomized Phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non small cell lung cancer. J. Thorac. Oncol. 13, 1156–1170 (2018).
  Medline CASGoogle Scholar
• 11. Fehrenbacher L , Spira A , Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non small cell lung cancer (POPLAR): a multicenter, open-label, Phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).
  Medline CASGoogle Scholar
• 12. Barlesi F , Vansteenkiste J , Spigel D et al. Avelumab versus docetaxel in patients with platinum-treated advanced non small cell lung cancer (JAVELIN Lung 200): an open-label, randomized, Phase 3 study. Lancet Oncol. 19(11), 1468–1479 (2018).
  Medline CASGoogle Scholar
• 13. Moher D , Liberati A , Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).
  MedlineGoogle Scholar
• 14. Jadad AR , Moore RA , Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1–12 (1996).
  Medline CASGoogle Scholar
• 15. R Core Team. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2017).
  Google Scholar
• 16. Viechtbauer W . Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36(3), 1–48 (2010).
  Google Scholar
• 17. Berkey CS , Hoaglin DC , Mosteller F , Colditz GA . A random-effects regression model for meta-analysis. Stat. Med. 14(4), 395–411 (1995).
  Medline CASGoogle Scholar
• 18. Van Houwelingen HC , Arends LR , Stijnen T . Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat. Med. 21(4), 589–624 (2002).
  MedlineGoogle Scholar
• 19. Hedges LV , Olkin I . Statistical Methods for Meta-Analysis. Academic Press, CA, USA (1985).
  Google Scholar
• 20. Raudenbush SW . Analyzing effect sizes: random effects models. In: The Handbook of Research Synthesis and Meta-analysis (2nd Edition). Cooper H Hedges LV Valentine JC (Eds). Russel Sage Foundation, NY, USA, 295–315 (2009).
  Google Scholar
• 21. Viechtbauer W . Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26(1), 37–52 (2007).
  MedlineGoogle Scholar
• 22. Der Simonian R , Laird N . Meta-analysis in clinical trials. Control Clin. Trials 7(3), 177–188 (1986).
  MedlineGoogle Scholar
• 23. Cochran WG . The combination of estimates from different experiments. Biometrics 10, 101–129 (1954).
  Google Scholar
• 24. Higgins JP , Thompson SG , Deeks JJ , Altman DG . Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).
  MedlineGoogle Scholar
• 25. Wu Y-L , Lu S , Cheng Y et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the Phase 3 CheckMate 078 study. Cancer Res. 78(13 Suppl.) Abstract CT114 (2018). • Key study demonstrating a greater efficacy with the anti-PD-1 nivolumab compared with standard chemotherapy in an Asian population.
  Google Scholar
• 26. Planchard D , Popat S , Kerr K et al. Metastatic non small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2018).
  Medline CASGoogle Scholar
• 27. Lee CK , Man J , Lord S et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 4(2), 210–216 (2018).
  MedlineGoogle Scholar
• 28. Fessas P , Lee H , Ikemizu S et al. A molecular and preclinical comparison of the PD-1 targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin. Oncol. 44, 136–140 (2017).
  Medline CASGoogle Scholar
• 29. Butte MJ , Keir ME , Phamduy TB et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007).
  Medline CASGoogle Scholar
• 30. Butte MJ , Pena-Cruz V , Kim MJ et al. Interaction of human PD-L1 and B7-1. Mol. Immunol. 45, 3567–3572 (2008).
  Medline CASGoogle Scholar
• 31. Yang J , Riella LV , Chock S et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo . J. Immunol. 187, 1113–1119 (2011).
  Medline CASGoogle Scholar
• 32. You W , Liu M , Miao JD et al. A network meta-analysis comparing the efficacy and safety of anti-PD-1 with anti-PD-L1 in non small cell lung cancer. J. Cancer 9, 1200–1206 (2018).
  MedlineGoogle Scholar
• 33. Passiglia F , Galvano A , Pantano F et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int. J. Cancer 142, 1277–1284 (2018).
  Medline CASGoogle Scholar
• 34. Pillai RN , Behera M , Owonikoko TK et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non small cell lung cancer: a systematic analysis of the literature. Cancer 124, 271–277 (2018).
  Medline CASGoogle Scholar
• 35. Khunger M , Rakshit S , Pasupuleti V et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chest 152, 271–281 (2017).
  MedlineGoogle Scholar